Avraham Pharmaceuticals Announces Commencement of a Phase II Study of Ladostigil for the Treatment of MCI

Avraham Pharmaceuticals announced the commencement of a Phase II clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI).
MarketWatch